إعلان
إعلان
BCAX
Bicara Therapeutics Inc. Common Stock
17.96
USDبرعاية
+1.40
+8.45%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
18.83
+0.87
+4.84%
تقارير أرباح BCAX
النسبة الإيجابية المفاجئة
BCAX تفوق 1 من 5 آخر التقديرات.
20%
التقرير التالي
بيانات التقرير القادم
٢٤ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.69
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+2.99%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/+76.92%
Bicara Therapeutics Inc. Common Stock earnings per share and revenue
On ١٠ نوفمبر ٢٠٢٥, BCAX reported earnings of -0.67 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -19.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 المحللين forecast an EPS of -0.69 USD, with revenue projected to reach -- USD, implying an زيادة of 2.99% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Bicara Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bicara Therapeutics Inc. Common Stock reported EPS of -$0.67, missing estimates by -19.6%, and revenue of $0.00, 0% as expectations.
How did the market react to Bicara Therapeutics Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.85%, changed from $14.64 before the earnings release to $13.93 the day after.
When is Bicara Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for ٢٤ مارس ٢٠٢٦.
What are the forecasts for Bicara Therapeutics Inc. Common Stock's next earnings report?
Based on 13
المحللين, Bicara Therapeutics Inc. Common Stock is expected to report EPS of -$0.69 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان